The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
|Videos|November 13, 2018
Nivolumab and Ipilimumab Combination in Frontline mCRC
Author(s)Michael J. Overman, MD
Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.
Advertisement
Michael J. Overman, MD, professor of gastrointestinal and medical oncology at The University of Texas MD Anderson Cancer Center, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in microsatellite instability-high metastatic colorectal cancer.
At 1 year, the progression-free survival was approximately 80% and the majority of patients had a response. This is dramatic activity to see in the frontline, Overman notes.
Advertisement
Related to this article
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.
The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
4
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
5